Table 2. Baseline factors and response to tolvaptan.
| Effective group Weight reduction ≥2%(n = 46) |
Ineffective group Weight reduction <2%(n = 42) |
P-value | |
|---|---|---|---|
| Age | 67.8±13.4 | 70.9±10.2 | 0.22 |
| Gender male/female | 30/16 | 27/15 | 0.99 |
| Child Pugh grade B/C | 32/14 | 26/12 | 0.5 |
| Etiology (HCV/HBV/ALD/others) | 28/0/12/6 | 19/3/10/10 | 0.05 |
| Co-exsisting of HCC | 17 | 23 | 0.13 |
| Furosemide (≦40/ >40mg/day) | 37/9 | 40/2 | 0.05 |
| Spironolactone (≦50/ >50mg/day) | 41/5 | 42/0 | 0.06 |
| Albumin (g/dL) | 2.6±0.5 | 2.6±0.6 | 0.94 |
| Total bilirubin (mg/dL) | 1.6±1.0 | 1.7±1.2 | 0.7 |
| Serum Creatinin (mg/dL) | 0.96±0.64 | 1.17±0.95 | 0.22 |
| eGFR (mg/min/1.73m2) | 70.3±28.2 | 59.1±28.3 | 0.07 |
| Serum Na (mEq/L) | 137.5±2.9 | 135.6±6.1 | 0.06 |
| CRP (mg/dL) | 0.76±0.96 | 1.51±1.63 | <0.05 |
| Platelet counts (×104/μL) | 8.7±5.4 | 11.5±6.3 | <0.05 |
| Prothrombin activity (%) | 72.6±18.2 | 70.7±20.6 | 0.66 |
| Urine osmolarity (mOsm/L) | 376±110 | 415±137 | 0.14 |
| Urine Na (mEq/L) | 76.5±27.5 | 57.3±33.4 | <0.05 |
| Urine K (mEq/L) | 19.6±9.6 | 26.8±13.8 | <0.05 |
| Urine Na/K | 4.5±2.3 | 2.7±2.0 | <0.05 |
HCV: hepatitis C virus, HBV: hepatitis B virus, ALD: alcoholic liver disease, HCC: hepatocellular carcinoma, ALT: alanine aminotransferase